Another study in a phase 1 trial evaluated trastuzumab in combination with durvalumab (anti-PD-L1) in metastatic HER2+ breast cancer patients and no impact on objective responses was observed and all the patients enrolled in the trials had lower than 1% PD-L1 expression (19). Here, ERBB2 is linked to breast carcinoma.